CCRM supports the commercialization of regenerative medicine-based technologies, and cell and gene therapies, with strategic funding, dedicated infrastructure and specialized business and scientific expertise.
By partnering with leading research institutions to launch new ventures, enabling industry by providing innovative contract development and manufacturing organization (CDMO) services, and scaling emerging companies by catalyzing investment, CCRM is accelerating the translation of promising technologies, processes and therapies into life-changing health outcomes for patients.
How CCRM is building a sustainable cell and gene therapy ecosystem
In 2021, we celebrated our 10-year anniversary. Catch up on our story so far by reading “The CCRM story: 10 years in the making” in the digital booklet below, or by clicking here to read it online. Click the open book icon to read, scroll to zoom, and double click near the page edges to pan across the book’s pages.